GAMMA Investing
PLX icon

GAMMA Investing’s Protalix BioTherapeutics PLX Stock Holding History

GAMMA Investing’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.73K Buy
627
+272
+77% +$677 ﹤0.01% 3980
2026
Q2 		$827 Sell
355
-124
-26% -$263 ﹤0.01% 3918
2026
Q1 		$1.04K Buy
479
+124
+35% +$308 ﹤0.01% 3829
2025
Q4 		$639 Buy
+355
New +$726 ﹤0.01% 3882

Other funds holding PLX

Concurrent Investment Advisors
Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return
Bailard
Bailard Foster City, California $4.94B AUM 25.15% 1-Year Est. Return
State of Alaska Department of Revenue
State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return
TD Waterhouse Canada
TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $540M AUM 34.92% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

GAMMA Investing's PLX Position: Q3 2026 in Review

GAMMA Investing increased its Protalix BioTherapeutics (PLX) stake by 77% in Q3 2026, buying an estimated $677 and bringing the position to 627 shares worth $1.73K. The position accounts for ﹤0.01% of the portfolio, ranked #3980.

GAMMA Investing first reported a position in PLX in Q4 2025 and has held it in 4 quarters since. 9 funds tracked by Wall St. Rank hold PLX as of Q3 2026.

  • GAMMA Investing held 627 shares of Protalix BioTherapeutics worth $1.73K as of Q3 2026.
  • GAMMA Investing bought 272 Protalix BioTherapeutics shares in Q3 2026, an estimated $677.
  • Protalix BioTherapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #3980 holding.
  • GAMMA Investing first reported a position in Protalix BioTherapeutics in Q4 2025 and has held it in 4 quarters since.
  • 9 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.